Embecta (EMBC) announced that the board of directors of Embecta has elected Devdatt Kurdikar as chairman of the board and Claire Pomeroy as lead independent director, effective immediately. These changes follow the previously announced retirement of David Melcher, non-executive chairman of the board due to several commitments outside of his service to the Company. Kurdikar joined Becton Dickinson in 2021 to lead the diabetes care business and became the president and CEO of the company and a member of its board of directors upon completion of its spinoff from BD in 2022.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMBC:
